{"id":"low-dose-carbamazepine","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Dizziness"},{"rate":"15-25","effect":"Ataxia / coordination problems"},{"rate":"15-20","effect":"Diplopia / blurred vision"},{"rate":"10-15","effect":"Nausea"},{"rate":"5-10","effect":"Hyponatremia"},{"rate":"1-3","effect":"Rash / Stevens-Johnson syndrome"},{"rate":"<1","effect":"Agranulocytosis"}]},"_chembl":{"chemblId":"CHEMBL108","moleculeType":"Small molecule","molecularWeight":"236.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Carbamazepine is an anticonvulsant that blocks voltage-gated sodium channels, reducing the repetitive firing of action potentials in neurons. At low doses, it may also modulate calcium channels and enhance GABAergic neurotransmission. This stabilization of neuronal membranes prevents seizure propagation and abnormal electrical discharges.","oneSentence":"Low-dose carbamazepine reduces sodium channel activity and stabilizes neuronal membranes to prevent abnormal electrical activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:53:11.737Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Epilepsy / seizure disorders"},{"name":"Trigeminal neuralgia"},{"name":"Bipolar disorder (off-label or approved depending on region)"}]},"trialDetails":[{"nctId":"NCT06547164","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-08-27","conditions":"Healthy Participants","enrollment":40},{"nctId":"NCT03689114","phase":"PHASE4","title":"Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW)","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-05-10","conditions":"Epilepsies, Partial","enrollment":58},{"nctId":"NCT04962230","phase":"PHASE1","title":"Drug-Drug Interaction Study Assessing Effect of Carbamazepine on PF-07321332 Boosted With Ritonavir","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-07-15","conditions":"Healthy Participant","enrollment":12},{"nctId":"NCT00807989","phase":"PHASE4","title":"The Efficacy and Safety of Low Dose Combination of LTG and VPA Compared to CBZ Monotherapy","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2008-03","conditions":"Epilepsy","enrollment":207}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":28,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["low carbamazepine"],"phase":"marketed","status":"active","brandName":"Low dose carbamazepine","genericName":"Low dose carbamazepine","companyName":"Mario Negri Institute for Pharmacological Research","companyId":"mario-negri-institute-for-pharmacological-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Low-dose carbamazepine blocks sodium channels in neuronal membranes, reducing repetitive neuronal firing and stabilizing the threshold for action potential generation. Used for Epilepsy, Trigeminal neuralgia, Bipolar disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}